dr. sikov on bevacizumab or carboplatin impact on tnbc subtype
Published 9 years ago • 252 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
1:56
dr. eric winer on carboplatin and/or bevacizumab in triple-negative breast cancer
-
0:48
dr. william sikov on triple-negative breast cancer patients not responding to treatment
-
0:35
dr. brufsky discusses bevacizumab benefits in tnbc
-
1:00
dr. kris on the impact of bevacizumab biosimilars in lung cancer
-
14:06
william m. sikov: calgb 40603
-
12:04
sabcs2014: calgb 40603/150709 (alliance): william m. sikov
-
9:03
is there a role for tnbc subtyping?
-
2:19
dr. arend on fda approval of frontline bevacizumab in ovarian cancer
-
1:12
dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer
-
1:07
dr. o'shaughnessy on avastin as her standard of care
-
1:05
dr. essel discusses long-term bevacizumab in ovarian cancer
-
7:06
tnt study in triple negative breast cancer
-
1:09
dr. herbst on the bevacizumab biosimilar in lung cancer
-
1:59
ovarian cancer subtypes may predict response to bevacizumab
-
11:01
william m sikov
-
1:56
dr. schmid on benefit of pembrolizumab in patients with tnbc
-
1:27
dr. reuben s. harris on apobec3b as a possible treatment variable in breast cancer
-
8:15
bevacizumab in ovarian cancer
-
1:17
dr. burstein discusses pathological complete response